Jun 8, 2026 · 7 min
S&P inclusion lifts Marvell and Flex as tech stocks rebound
Marvell Rallies on S&P Add; Micron Rebounds; Lilly Gains on Obesity Drugs
The episode examines how index-fund flows, a tech-sector recovery, and drug-market competition are reshaping individual stock valuations.
- 1Marvell Technology and Flex gain after joining the S&P 500, highlighting the market impact of passive investment funds.
- 2Micron Technology rebounds after a sharp technology sell-off, while broader sector momentum remains central to its recovery.
- 3Eli Lilly and Nurix Therapeutics reflect intensifying competition across obesity and cancer treatments.
Don't miss
Marvell Technology and Flex rally after entering the S&P 500, illustrating how passive-fund demand can affect valuations.
The brief
Marvell Technology and Flex rally after their addition to the S&P 500, putting passive investment flows at the center of the market’s reaction.
Micron Technology’s rebound follows a sharp technology sell-off, showing how quickly sentiment can shift across a crowded sector.
The pharmaceutical discussion turns to Eli Lilly and Nurix Therapeutics, where obesity and cancer treatments create distinct competitive pressures.
Taken together, the episode contrasts index-driven demand with company-specific drug developments, asking what is really moving these stocks.
Featuring
Listen to the full episode and explore every guest, topic, and moment on PodLume.